Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more
Cyclopharm Ltd (CYC) - Total Liabilities
Latest total liabilities as of June 2025: AU$19.81 Million AUD
Based on the latest financial reports, Cyclopharm Ltd (CYC) has total liabilities worth AU$19.81 Million AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cyclopharm Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how Cyclopharm Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cyclopharm Ltd Competitors by Total Liabilities
The table below lists competitors of Cyclopharm Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pylon Public Company Limited
BK:PYLON
|
Thailand | ฿328.92 Million |
|
Chin Yang Ind
KO:003780
|
Korea | ₩28.66 Billion |
|
Everfuel AS
OL:EFUEL
|
Norway | Nkr36.86 Million |
|
Media Prima Bhd
KLSE:4502
|
Malaysia | RM721.73 Million |
|
Dagi Giyim Sanayi ve Ticaret AS
IS:DAGI
|
Turkey | TL2.35 Billion |
|
Tokens.com Corp.
OTCQB:XBOTF
|
USA | $2.75 Million |
|
Brazilian Critical Minerals Ltd
AU:BCM
|
Australia | AU$1.29 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Cyclopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclopharm Ltd (2005–2024)
The table below shows the annual total liabilities of Cyclopharm Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$19.40 Million | +42.05% |
| 2023-12-31 | AU$13.65 Million | +4.99% |
| 2022-12-31 | AU$13.01 Million | +2.62% |
| 2021-12-31 | AU$12.67 Million | +13.57% |
| 2020-12-31 | AU$11.16 Million | +19.68% |
| 2019-12-31 | AU$9.32 Million | +43.00% |
| 2018-12-31 | AU$6.52 Million | +6.41% |
| 2017-12-31 | AU$6.13 Million | +55.01% |
| 2016-12-31 | AU$3.95 Million | +14.96% |
| 2015-12-31 | AU$3.44 Million | +7.29% |
| 2014-12-31 | AU$3.21 Million | -40.08% |
| 2013-12-31 | AU$5.35 Million | -11.56% |
| 2012-12-31 | AU$6.05 Million | -9.58% |
| 2011-12-31 | AU$6.69 Million | -20.15% |
| 2010-12-31 | AU$8.38 Million | +46.54% |
| 2009-12-31 | AU$5.72 Million | +3.47% |
| 2008-12-31 | AU$5.52 Million | +51.95% |
| 2007-12-31 | AU$3.64 Million | -62.24% |
| 2006-12-31 | AU$9.63 Million | -0.29% |
| 2005-12-31 | AU$9.66 Million | -- |